Sysmex (OTCMKTS:SSMXY) versus Neuronetics (NASDAQ:STIM) Head-To-Head Contrast

Sysmex (OTCMKTS:SSMXY) and Neuronetics (NASDAQ:STIM) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends.

Earnings & Valuation

This table compares Sysmex and Neuronetics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sysmex	$3.32 billion	2.38	$234.01 million	$0.42	30.89
Neuronetics	$149.16 million	0.76	-$39.00 million	($0.33)	-4.41

Sysmex has higher revenue and earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Sysmex, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Sysmex has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, Neuronetics has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.

Institutional and Insider Ownership

53.6% of Neuronetics shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Sysmex and Neuronetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sysmex	6.38%	6.81%	4.72%
Neuronetics	-14.45%	-102.23%	-16.83%

Analyst Recommendations

This is a summary of current ratings and price targets for Sysmex and Neuronetics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sysmex	0	2	0	0	2.00
Neuronetics	1	0	4	0	2.60

Neuronetics has a consensus price target of $5.00, indicating a potential upside of 243.64%. Given Neuronetics’ stronger consensus rating and higher possible upside, analysts clearly believe Neuronetics is more favorable than Sysmex.

Summary

Sysmex beats Neuronetics on 8 of the 14 factors compared between the two stocks.

About Sysmex

Sysmex Corporation is a Japan-based healthcare technology company that develops, manufactures and sells diagnostic testing instruments, reagents and related services. Its products are used by hospitals, clinical laboratories and other healthcare providers to analyze patient samples and support medical diagnosis. The company is best known for its hematology testing systems and also offers products for hemostasis, urinalysis, clinical chemistry and immunochemistry, as well as laboratory information systems and support services.

About Neuronetics

Neuronetics, Inc. is a medical technology company that develops and commercializes noninvasive treatments for certain mental health conditions. Its flagship product is the NeuroStar Advanced Therapy System, which uses transcranial magnetic stimulation to deliver targeted magnetic pulses to areas of the brain. NeuroStar is FDA-cleared for treating major depressive disorder in adults who have not achieved satisfactory improvement with antidepressant medication. The company also provides treatment-related services and support for clinicians and patients.